New formulations of amoxicillin/clavulanic acid: A pharmacokinetic and pharmacodynamic review

Clinical Pharmacokinetics

Volumn 44, Issue 11, 2005, Pages 1097-1115

  Navarro, Amparo Sánchez ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLAVULANIC ACID;

AREA UNDER THE CURVE; BIOAVAILABILITY; CLINICAL TRIAL; DRUG EFFECT; DRUG FORMULATION; GASTROINTESTINAL ABSORPTION; HAEMOPHILUS INFLUENZAE; HUMAN; MEMBRANE TRANSPORT; METHODOLOGY; MORAXELLA CATARRHALIS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS PNEUMONIAE; THEORETICAL STUDY;

AMOXICILLIN; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; CHILD; CLAVULANIC ACID; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HAEMOPHILUS INFLUENZAE; HUMANS; MORAXELLA (BRANHAMELLA) CATARRHALIS; STREPTOCOCCUS PNEUMONIAE;

EID: 26944467189     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200544110-00001     Document Type: Review

References (97)

1. Klein O. Amoxicillin/clavulanate for infections in infants and children: past, present and future. Pediatr Infect Dis J 2003; 22 (8 Suppl.): S139-48
2. White AR, Kaye C, Poupard J, et al. Augmentine (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother 2004; 53 Suppl. 1: i3-20
3. Easton J, Noble S, Perry CM. Amoxicillin/clavulanic acid. Drugs 2003; 63 (3): 311-40
4. Charles BG, Prechagoon Y, Lee TC, et al. Population pharmacokinetics of intravenous amoxicillin in very low birth weight infants. J Pharm Sci 1997; 86: 1288-92
5. Huisman-de Boer JJ, van den Anker JN, Vogel M, et al. Amoxicillin pharmacokinetics in preterm infants with gestational ages of less than 32 weeks. Antimicrob Agents Chemother 1995; 39: 431-4
6. Calver AD, Wals NS, Quinn PF. Dosing of amoxicillin/clavulanate given every 12 hours is as effective as dosing every 8h for the treatment of lower respiratory tract infection. Clin Infect Dis 1997; 24: 570-4
7. Sourgens H, Bertola MA, Verschoor JSC, et al. Amoxicillin/clavulanic acid (875/125): bioequivalence of a novel solutab tablet and rational for a twice-daily dosing regimen. Int J Clin Pharmacol Ther 2004; 42: 165-73
8. Benninger MS. Amoxicillin/clavulanate extended release tablets: a new antimicrobial for the treatment of acute bacterial sinusitis and community-acquired pneumonia. Exp Opi Pharmacother 2003; 4 (10): 1839-46
9. Staniforth DH, Jackson D, Clarke HL, et al. Amoxicillin/clavulanic acid: the effect of probenecid. J Antimicrob Chemother 1983; 12: 273-5
10. Zarowny DR, Ogilvie D, Tamlyn D, et al. Pharmacokinetics of amoxicillin. Clin Pharmacol Ther 1974; 16: 1045-51
11. Arancibia A, Guttmann J, González G, et al. Absorption and disposition kinetics of amoxicillin in normal human subjects. Antimicrob Agents Chemother 1980; 17 (2): 199-202
12. Spyker DA, Rugloski RJ, Vann RL, et al. Pharmacokinetics of amoxicillin: dose dependence after intravenous, oral, and intramuscular administration. Antimicrob Agents Chemother 1977; 11 (1): 132-41
13. Grange JD, Gouyette A, Gutmann L, et al. Pharmacokinetics of amoxicillin/clavulanic in serum and ascitic fluid in cirrhotic patients. J Antimicrob Chemother 1989; 23: 605-11
14. Reed MD. Clinical pharmacokinetics of amoxicillin and clavulanate. Pediatr Infect Dis J 1996; 15 (10): 949-54
15. Weismeier K, Adam D, Heilmann HD, et al. Penetration of amoxycillin/clavulanate into human bone. J Antimicrob Chemother 1989; 24 Suppl. B: 93-100
16. Todd PA, Benfield P. Amoxicillin/clavulanic acid an update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1990; 39 (2): 264-307
17. Reed MD. The clinical pharmacology of amoxicillin and clavulanic acid. Pediatr Infect Dis J 1998; 17 (10): 957-62
18. Lovering AM, Pycock CJ, Harvey JE, et al. The pharmacokinetics and sputum penetration of ampicillin and amoxicillin following simultaneous iv administration. J Antimicrob Chemother 1990; 25: 385-92
19. Cox AL, Meewis JM, Horton R. Penetration into lung tissue after intravenous administration of amoxicillin/clavulanate. J Antimicrob Chemother 1989; 24 Suppl. B: 87-91
20. Cook PJ, Andrews JM, Woodcock J, et al. Concentration of amoxicillin and clavulanate in lung compartments in adults without pulmonary infection. Thorax 1994; 49: 1134-8
21. Gould IM, Harvey G, Golder D, et al. Penetration of amoxicillin/ clavulanic acid into bronchial mucosa with different dosing regimens. Thorax 1994; 49: 999-1001
22. Bakken JS, Brunn JN, Gaustad P, et al. Penetration of amoxicillin and potassium clavulanate into the cerebrospinal fluid of patients with inflamed meninges. Antimicrob Agents Chemother 1986; 30 (3): 481-4
23. Decazes JM, Bure A, Wolff M, et al. Bactericidal activity against Haemophilus influenzae of cerebrospinal fluid of patients given amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1987; 31 (12): 2018-9
24. Dinis PB, Monteiro MC, Martins ML, et al. Sinus tissue pharmacokinetics after oral administration of amoxicillin/clavulanic acid. Laryngoscope 2000; 110 (6): 1050-5
25. Ginsburg CM, Mccracken GH, Zweighaft TC, et al. Comparative pharmacokinetics of cyclacillin and amoxicillin in infants and children. Antimicrob Agents Chemother 1981; 19 (6): 1086-8
26. Schaad UB, Casey PA, Cooper DL. Single-dose pharmacokinetics of intravenous clavulanic acid with amoxicillin in pediatric patients. Antimicrob Agents Chemother 1983; 23: 242-55
27. Seikel K, Shelton S, Mccracken JR. Middle ear fluid concentrations of amoxicillin after large dosages in children with acute otitis media. Pediatr Infect Dis J 1998; 17 (10): 969-70
28. Canafax DM, Chonmaitree YZ, Deka T, et al. Amoxicillin middle ear fluid penetration and pharmacokinetics in children with acute otitis media. Pediatr Infect Dis J 1998; 17 (2): 149-56
29. Harrison CJ, Welch DF. Middle ear effusion amoxicillin concentrations in acute otitis media. Pediatr Infect Dis J 1998; 17 (7): 657-8
30. Scaglione F, Caronzolo D, Pintucci JP, et al. Measurement of cefaclor and amoxicillin-clavulanic acid levels in middle-ear fluid in patients with acute otitis media. Antimicrob Agents Chemother 2003; 47: 2987-9
31. Fonseca W, Hoppu K, Rey LC, et al. Comparing pharmacokinetics of amoxicillin given twice or three times per day to children older than 3 months with pneumonia. Antimicrob Agents Chemother 2003; 47 (3): 997-1001
32. Molinaro M, Corona G, Fiorito V, et al. Bioavailability of two different oral formulations of amoxicillin in healthy subjects. Arzneimittelforschung 1997; 47 (12): 1406-10
33. Jacobs MR. Building in efficacy: developing solutions to combat drug-resistant S. pneumoniae. Clin Microbiol Infec 2004; 10 Suppl. 2: 18-27
34. Welling PG, Huang H, Kock PA, et al. Bioavailability of ampicillin and amoxicillin in fasted and non-fasted subjects. J Pharm Sci 1977; 66: 549-52
35. Tsuji A, Nakashima E, Kagami I, et al. Intestinal absorption mechanism of amphoteric β-lactam antibiotics: I. Comparative absorption and evidence for saturable transport of amino-β-lactam antibiotics by in situ rat small intestine. J Pharm Sci 1981; 70 (7): 768-72
36. Sjovall J, Alván G, Westerlund D. Dose-dependent absorption of amoxicillin and bacampicillin. Clin Pharmacol Ther 1985; 38: 241-50
37. Arancibia A, Icarte A, González C, et al. Dose-dependent bioavailability of amoxicillin. Int J Clin Pharmacol Ther Toxicol 1988; 26 (6): 300-3
38. Torres-Molina F, Peris-Ribera E, García-Carbonell MC, et al. Nonlinearities in amoxicillin pharmacokinetics: II. Absorption studies in the rat. Biopharm Drug Dis 1992; 13: 39-53
39. Paintaud AG, Dahl ML, Grahnén Sjövall J, et al. Nonlinearity of amoxicillin absorption kinetics in human. Eur J Clin Pharmacol 1992; 43: 283-8
40. Piotrovskij VK, Paintaud G, Alván G, et al. Modeling of the saturable time-constrained amoxicillin absorption in humans. Pharm Res 1994; 11 (9): 1346-51
41. Barr WH, Zola EM, Candler EL, et al. Differential absorption of amoxicillin from the human small and large intestine. Clin Pharmacol Ther 1994, 285
42. Chulavatnatol S, Charles BG. Determination of dose-dependent absorption of amoxicillin from urinary excretion data in healthy subjects. Br J Clin Pharmacol 1994; 38: 274-7
43. Vree TB, Dammers E, Exler PS. Identical pattern of highly variable absorption of clavulanic acid from four different oral formulations of co-amoxiclav in healthy subjects. J Antimicrob Chemother 2003; 51: 373-8
44. Arancibia A, Droguett MT, Fuentes G, et al. Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function. Int J Clin Pharmacol Ther Toxicol 1982; 20: 447-52
45. Adam D, Visser I, Koeppe P. Pharmacokinetics of amoxicillin and clavulanic acid administered alone and in combination. Antimicrob Agents Chemother 1982; 22 (3): 353-7
46. Vree TB, Dammers E, van Duren E. Variable absorption of clavulanic acid after an oral dose of 25 mg/kg of clavubactin and synulox in healthy cats. Sci World J 2002; 2: 1969-78
47. Vree TB, Dammers E, Van Duuren E. Variable absorption of clavulanic acid after an oral dose of 25 mg/kg of clavubactin and synulox in healthy dogs. J Vet Pharmacol Therap 2003; 26: 165-71
48. Hunter PA, Coleman K, Fisher J, et al. In vitro synergistic properties of clavulanic acid, with ampicillin, amoxicillin and ticarcillin. J Antimicrob Chemother 1980; 6: 455-70
49. Watson ID, Bulton-Jones M, Stewart J, et al. Pharmacokinetics of clavulanic acid-potentiated ticarcillin in renal failure. Ther Drug Monitor 1987; 9 (2): 139-47
50. Nelson J, Kusmiesz H, Shelton S. Pharmacokinetics of potassium clavulanate in combination with amoxicillin in pediatric patients. Antimicrob Agents Chemother 1982; 21 (4): 681-2
51. Jones AE, Barnes ND, Tasker TCG, et al. Pharmacokinetics of intravenous amoxicillin and potassium clavulanate in seriously ill children. J Antimicrob Chemother 1990; 25: 269-74
52. Bolton GC, Allen GD, Davies BE, et al. The disposition of clavulanic acid in man. Xenobiotica 1986; 116: 853-63
53. Allen GD, Coates PE, Davies BE. On the absorption of clavulanic acid. Biopharm Drug Disposition 1988; 9: 127-36
54. Witkowski G, Lode H, Hofken G, et al. Pharmacokinetic studies of amoxicillin, potassium clavulanate and their combination. Eur J Clin Microbiol 1982; 1: 233-7
55. Sinko PJ, Amidon GL. Characterization of the oral absorption of β-lactam antibiotics: II. Competitive absorption and peptide carrier specificity. J Pharm Sci 1989; 78 (9): 723-7
56. Kaye CM, Allen A, Perry S, et al. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Clin Ther 2001; 23 (4): 578-84
57. Turnidge JD. The pharmacodynamics of β-lactams. Clin Infect Dis 1998; 27: 10-22
58. Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Clin Pharmacokinet 1995; 28 (2): 143-60
59. Mouton JW, Vinks ATM. Is continuous infusion of β-lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations. J Antimicrob Chemother 1996; 38: 5-15
60. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1988; 26: 1-12
61. Ambrose PG, Grasela TH, Passarell J, et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infection. Antimicrob Agents Chemother 2001; 45: 2793-7
62. MacGowan AP. Elements of design: the knowledge on which we build. Clin Microb Infect 2004; 10 Suppl. 2: 6-11
63. Andes D, Craig WA. In vivo activities of amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 1998; 42 (9): 2375-9
64. Craig WA. Proof of concept: performance testing in models. Clin Microb Infect 2004; 10 Suppl. 2: 12-7
65. Dagan R, Klugman KP, Craig WA, et al. Evidence to support the rationale that bacterial eradication in respiratory tract infections is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001; 47: 129-40
66. Craig WA, Gudmundsson S. The postantibiotic effect. In: Lorian V, editor. Antibiotics in laboratory medicine. 2nd ed. Baltimore (MD): Williams and Wilkins, 1986: 515-63
67. Thorburn CE, Molesworth SJ, Sutherland R, et al. Postantibiotic and post-β-lactamase inhibitor effects of amoxicillin plus clavulanate. Antimicrob Agents and Chemother 1996; 40 (12): 2796-801
68. Lister PD, Pong A, Chartrand SA, et al. Rationales behind high-dose amoxicillin therapy for acute otitis media due to penicillin-nonsusceptible pneumococci: support from in vitro pharmacodynamic studies. Antimicrob Agents Chemother 1997; 41 (9): 1926-32
69. Sanders MA, Korzeniowski OM, Allegro GM, et al. Intermittent or continuous therapy of experimental meningitis due to Streptococcus pneumonia in rabbits: preliminary observations of the postantibiotic effect in vivo. Rev Infect Dis 1981; 3: 98-109
70. Andes D, Urban A, Craig WA. In vivo activity of amoxicillin (amox) and amoxicillin/clavulanate (amox/clav) against penicillin-resistant pneumococci [abstract no. A82]. In: Abstracts of the 35th International Conference of Antimicrobial Agents and Chemotherapy; 1995 Sep 17-20; San Francisco (CA). Washington, DC: American Society for Microbiology, 1995
71. Moine P, Mazoit JX. Streptococcus pneumoniae pneumonia in mice: optimal amoxicillin dosing predicted from a pharmacokinetic-pharmacodynamic model. J Pharmacol Exp Ther 199; 291: 1086-92
72. Thorburn CE, Molesworth SJ. The post beta-lactamase inhibitor effect (PLIE): a novel aspect of the activity of clavulanic acid in antibacterial test [abstract no. 540]. In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1992 Oct 11-14; Anaheim (CA). Washington, DC: American Society for Microbiology, 1992
73. Knudsen JD, Odenholt I, Erlendsdottir H. Selection of resistant Streptococcus pneumoniae during penicillin treatment in vitro and three animal models. Antimicrob Agents Chemother 2003; 47: 2499-506
74. Reading C, Cole M. Clavulanate: a beta-lactamase-inhibiting beta-lactam from Streptomyces clavuligerus. Antimicrob Agents Chemother 1977; 11: 852-7
75. Rolinson GN. A review of the microbiology of amoxicillin/clavulanate over the 15 year period 1978-1993. J Chemother 1994; 6: 283-318
76. Ball P, Geddes A, Rolinson GN. Amoxicillin clavulanate: an assessment after 15 years of clinical application. J Chemother 1997; 9: 167-98
77. Cooper CE, Slocombe B, White AR. Effect of low concentrations of clavulanic acid on the in-vitro activity of amoxicillin against β-lactamase-producing Branhamella catarrhalis and Haemophilus influenzae. J Antimicrob Chemother 1990; 26: 371-80
78. Finlay J, Miller L, Poupard JA. A review of the antimicrobial activity of clavulanate. J Antimicrob Chemother 2003; 52: 18-23
79. Severin A, Severina E, Tomasz A. Abnormal physiological properties and altered cell wall composition in Streptococcus pneumoniae grown in the presence of clavulanic acid. Antimicrob Agents Chemother 1997; 41 (3): 504-10
80. Cottagnoud P, Tomasz A. Triggering of pneumococcal autolysins by lysozyme. J Infect Dis 1993; 167: 684-90
81. Pozzi G, Oggioni MR, Tomasz A. DNA probe for identification of Streptococcus pneumoniae. J Clin Microb 1989; 27: 370-2
82. Cuffini AM, Tullio V, Ciacchino F, et al. Improved phagocyte response by co-amoxiclav in renal transplant recipients. Transplantation 2001; 71: 575-7
83. Smith GM, Slocombe B, Abbott KH. Activity of amoxicillin/clavulanate against penicillin-resistant Streptococcus pneumoniae in an experimental respiratory infection model in rats. Antimicrob Agents Chemother 1998; 42: 813-7
84. Martín M, Gomez-Lus ML, Aguilar L. Effect of clavulanic acid and/or polymorphonuclear neutrophils on amoxicillin bactericidal activity against Streptococcus pneumoniae. Eur J Clin Microb Infect Dis 1997; 16: 512-6
85. Cuffini AM, Tullio V, Palarchio IA. Enhanced effects of amoxicillin/clavualanate compared with amoxicillin and clavulanate alone on the susceptibility to inmmunodefenses of a penicillin-resistant strain of Streptococcus pneumoniae. Drugs Exp Clin Res 1998; 24: 173-84
86. Lee C, Blaser J, Lthy R. Post antibiotic effect (PAE) is markedly influenced by shaking conditions during exposure to antibiotic concentrations [abstract no. 383]. In: Program and abstracts of the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1982 Oct 4-6; Miami Beach (FL). Washington, DC: American Society for Microbiology, 1982
87. Chan KH, Mandel EM, Rockette HE. A comparative study of amoxicillin-clavulanate and amoxicillin: treatment of otitis media with effusion. Arch Otolaryngol Head Neck Surg 1988; 114: 142-6
88. Patel JA, Reisner B, Vizirinia N. Bacteriologic failure of amoxicillin-clavulanate in treatment of acute otitis media caused by nontypeable Haemophilus influenzae. J Pediatric 1995; 126: 799-806
89. Wald ER, Chiponis D, Ledesma-Medina J. Comparative effectiveness of amoxicillin and amoxicillin-clavulanate potassium in acute paranasal sinus infections in children: a double-blind, placebo-controlled trial. Pediatrics 1986; 77: 795-800
90. Dagan R. Achieving bacterial eradication using pharmacokinetic/ pharmacodynamic principles. Int J Infect Dis 2003; 7 Suppl. 1: S21-6
91. Lowdin E, Cars O, Odenholt I. Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens including a pharmacokinetically enhanced formulations. Clin Microb Infect 2002; 8 (10): 646-53
92. MacGowan AP, Bowker KE, Wooten M, et al. The activity of once a day moxifloxacin against Streptococcus pnemoniae explored using a pharmacodynamic model. Antimicrob Agents Chemother 1999; 43: 1560-9
93. Noel AN, MacGowan AP, Bowker KE. Effect of bacterial load on the pharmacodynamics of pharmacokinetically enhanced co-amoxiclav against Streptococcus pneumoniae studied in an in vitro model [abstract no. A506). In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego (CA). Washington, DC: American Society for Microbiology, 2002: 6
94. Berry V. Effect of a pharmacokinetically enhanced formulation of amoxicillin/clavulanate against experimental respiratory tract infection (RTI) in rats caused by Streptococcus pneumoniae [abstract no. B988]. In: Abstracts from the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16-19; Chicago (IL). Washington, DC: American Society for Microbiology, 2001: 53
95. Ambrose PG, Grasela DM. The use of Monte Carlo simulation to examine pharmcodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diag Microb Infect Dis 2000; 38: 151-7
96. Nicolau DP, Ambrose PG. Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae. Am J Med 2001; 111 Suppl. 9A: 13-18S
97. Sánchez Navarro A, Colino Gandarillas C-I, Alvárez Lerma F, et al. Pharmacokinetics and pharmacodynamics of levofloxacin in intensive care patients. Clin Pharmacokinet 2005; 44 (6): 627-35